# Selective β2-AR Antagonism in Asthma

> **NCT07272135** · PHASE1 · COMPLETED · sponsor: **Trio Medicines Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** TR4
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07272135
- **Lead sponsor:** Trio Medicines Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2022-08-16
- **Final completion:** 2022-08-16
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07272135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07272135, "Selective β2-AR Antagonism in Asthma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07272135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*